EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Biweekly CAPOX versus triweekly CAPOX in the adjuvant therapy of post-surgery CRC: A randomized controlled trial

Hangyu Zhang iD, Danyang Wang, Zhou Tong, Tao Xiang, Xudong Zhu, Lulu Liu, Yi Zheng, Peng Zhao, Weijia Fang, Wenbin Chen

PLOS One · 2025

DOI: 10.1371/journal.pone.0313472 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift PLOS One, 2025. Verfasst von Hangyu Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, P. R. China. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Capecitabine, Oxaliplatin, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Zhejiang Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

This study aims to compare the safety and efficiency of modified biweekly CAPOX and conventional triweekly CAPOX in high-risk stage II and stage III post-surgery colorectal (CRC) patients.

Methods

From July 25, 2018, to May 14, 2021, high-risk stage II and stage III post-surgery CRC patients were randomized in the control triweekly group (intravenous infusion of oxaliplatin 130 mg/m 2 on day 1 and oral capecitabine 1000 mg/m 2 , twice daily from day 1 to day 14) and the experimental biweekly group (intravenous infusion of oxaliplatin 85 mg/m 2 on day 1 and oral capecitabine 1000 mg/m 2 , twice daily from day 1 to day 10). The primary endpoint was the incidence rate of thrombocytopenia. The secondary endpoint was 3-year disease free survival (DFS) rate. The patients follow up was started on July 25, 2018, and finished on October 8, 2024.

Results

A total of 160 patients were 1:1 randomly assigned (80 patients to biweekly group and 80 patients to triweekly group). All grade thrombocytopenia occurred in 33% and 49% patients at biweekly and triweekly group, respectively ( P = 0.02). Neutropenia presented in 36% and 51% patients at biweekly and triweekly group, respectively ( P = 0.04). The second endpoint 3-year DFS was 85.1% in biweekly group and 80.4% in triweekly CAPOX group ( P = 0.51, HR = 0.78, [95%CI, 0.38–1.63]). The total rate of uncomplete therapy patient was 7.5% and 15% in biweekly and triweekly group, respectively ( P = 0.13).

Conclusion

Biweekly CAPOX presented significant less thrombocytopenia and neutropenia than triweekly CAPOX regimen. There was no difference in 3-year DFS between biweekly CAPOX and triweekly CAPOX. Clinical trial registration: ClinicalTials.gov (NCT03564912).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsCapecitabineOxaliplatinAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleMiddle AgedAgedThrombocytopeniaChemotherapy, AdjuvantAdultDisease-Free SurvivalDrug Administration Schedule

Substanzen

CapecitabineOxaliplatin

Autor:innen und Institutionen

  • Department of Medical Oncology, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, P. R. China.
  • Department of colorectal surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, P. R. China.

ORCID-Profile: Hangyu Zhang

Förderung

  • Natural Science Foundation of Zhejiang Province

Zitieren

APA

Zhang, H., Wang, D., Tong, Z., Xiang, T., Zhu, X., Liu, L., Zheng, Y., Zhao, P., Fang, W., & Chen, W. (2025). Biweekly CAPOX versus triweekly CAPOX in the adjuvant therapy of post-surgery CRC: A randomized controlled trial. PLOS One. https://doi.org/10.1371/journal.pone.0313472

Vancouver

Zhang H, Wang D, Tong Z, Xiang T, Zhu X, Liu L, et al. Biweekly CAPOX versus triweekly CAPOX in the adjuvant therapy of post-surgery CRC: A randomized controlled trial. PLOS One. 2025. doi:10.1371/journal.pone.0313472

BibTeX
@article{Zhang2025,
  author = {Zhang, Hangyu and Wang, Danyang and Tong, Zhou and Xiang, Tao and Zhu, Xudong and Liu, Lulu and Zheng, Yi and Zhao, Peng and Fang, Weijia and Chen, Wenbin},
  title = {Biweekly CAPOX versus triweekly CAPOX in the adjuvant therapy of post-surgery CRC: A randomized controlled trial},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0313472}
}
Kostenlos starten →